{"id":"https://openalex.org/W2625769798","doi":"https://doi.org/10.1002/art.40186","title":"Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK\u20101 Inhibitor, After Short\u2010Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials","display_name":"Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK\u20101 Inhibitor, After Short\u2010Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials","publication_year":2017,"publication_date":"2017-06-16","ids":{"openalex":"https://openalex.org/W2625769798","doi":"https://doi.org/10.1002/art.40186","mag":"2625769798","pmid":"https://pubmed.ncbi.nlm.nih.gov/28622463","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5656813"},"language":"en","primary_location":{"id":"doi:10.1002/art.40186","doi":"https://doi.org/10.1002/art.40186","is_oa":true,"landing_page_url":"https://doi.org/10.1002/art.40186","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.40186","source":{"id":"https://openalex.org/S4210186158","display_name":"Arthritis & Rheumatology","issn_l":"2326-5191","issn":["2326-5191","2326-5205"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.40186","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111875619","display_name":"Fr\u00e9d\u00e9ric P. Vanhoutte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85459889","display_name":"Galapagos (Belgium)","ror":"https://ror.org/04e4j5d46","country_code":"BE","type":"company","lineage":["https://openalex.org/I85459889"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Fr\u00e9d\u00e9ric Vanhoutte","raw_affiliation_strings":["Gal\u00e1pagos NV Mechelen Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gal\u00e1pagos NV Mechelen Belgium","institution_ids":["https://openalex.org/I85459889"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065050213","display_name":"Minodora Mazur","orcid":"https://orcid.org/0000-0003-4562-1452","observed_orcids":["https://orcid.org/0000-0003-4562-1452"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Minodora Mazur","raw_affiliation_strings":["University Hospital, Chisinau, Moldova"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital, Chisinau, Moldova","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110499569","display_name":"O.I. Voloshyn","orcid":"https://orcid.org/0000-0001-6833-8022","observed_orcids":["https://orcid.org/0000-0001-6833-8022","https://orcid.org/0000-0003-2500-4705"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Oleksandr Voloshyn","raw_affiliation_strings":["Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039796536","display_name":"Mykola Stanislavchuk","orcid":"https://orcid.org/0000-0001-8160-8189","observed_orcids":["https://orcid.org/0000-0001-8160-8189"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mykola Stanislavchuk","raw_affiliation_strings":["Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101525167","display_name":"Annegret Van der Aa","orcid":"https://orcid.org/0000-0001-9095-8164","observed_orcids":["https://orcid.org/0000-0001-9095-8164"]},"institutions":[{"id":"https://openalex.org/I85459889","display_name":"Galapagos (Belgium)","ror":"https://ror.org/04e4j5d46","country_code":"BE","type":"company","lineage":["https://openalex.org/I85459889"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Annegret Van der Aa","raw_affiliation_strings":["Gal\u00e1pagos NV Mechelen Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gal\u00e1pagos NV Mechelen Belgium","institution_ids":["https://openalex.org/I85459889"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058667154","display_name":"Florence Namour","orcid":"https://orcid.org/0000-0002-8273-5451","observed_orcids":["https://orcid.org/0000-0002-8273-5451"]},"institutions":[{"id":"https://openalex.org/I4210112084","display_name":"Galapagos (France)","ror":"https://ror.org/023bt3h76","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210112084","https://openalex.org/I85459889"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Florence Namour","raw_affiliation_strings":["Gal\u00e1pagos SASU Romainville France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gal\u00e1pagos SASU Romainville France","institution_ids":["https://openalex.org/I4210112084"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023181600","display_name":"Ren\u00e9 Galien","orcid":"https://orcid.org/0000-0003-4199-9263","observed_orcids":["https://orcid.org/0000-0003-4199-9263"]},"institutions":[{"id":"https://openalex.org/I4210112084","display_name":"Galapagos (France)","ror":"https://ror.org/023bt3h76","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210112084","https://openalex.org/I85459889"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Ren\u00e9 Galien","raw_affiliation_strings":["Gal\u00e1pagos SASU Romainville France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gal\u00e1pagos SASU Romainville France","institution_ids":["https://openalex.org/I4210112084"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085035863","display_name":"Luc Meuleners","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85459889","display_name":"Galapagos (Belgium)","ror":"https://ror.org/04e4j5d46","country_code":"BE","type":"company","lineage":["https://openalex.org/I85459889"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Luc Meuleners","raw_affiliation_strings":["Gal\u00e1pagos NV Mechelen Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gal\u00e1pagos NV Mechelen Belgium","institution_ids":["https://openalex.org/I85459889"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110119590","display_name":"Gerben A.E. van 't Klooster","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85459889","display_name":"Galapagos (Belgium)","ror":"https://ror.org/04e4j5d46","country_code":"BE","type":"company","lineage":["https://openalex.org/I85459889"]}],"countries":["BE"],"is_corresponding":true,"raw_author_name":"Gerben van 't Klooster","raw_affiliation_strings":["Gal\u00e1pagos NV Mechelen Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gal\u00e1pagos NV Mechelen Belgium","institution_ids":["https://openalex.org/I85459889"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5110119590"],"corresponding_institution_ids":["https://openalex.org/I85459889"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":{"value":5190,"currency":"USD","value_usd":5190},"fwci":10.2769,"has_fulltext":true,"cited_by_count":82,"citation_normalized_percentile":{"value":0.99030614,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"69","issue":"10","first_page":"1949","last_page":"1959"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13026","display_name":"Natural Compounds in Disease Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2707","display_name":"Complementary and alternative medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/filgotinib","display_name":"filgotinib","score":1.0},{"id":"https://openalex.org/keywords/jak1-inhibitor","display_name":"JAK1 inhibitor","score":0.8600000143051147},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9890000224113464},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.699999988079071},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7749999761581421},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":1.0},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6980000138282776},{"id":"https://openalex.org/keywords/acr20-response","display_name":"ACR20 response","score":0.8190000057220459},{"id":"https://openalex.org/keywords/c-reactive-protein","display_name":"C-reactive protein","score":0.7680000066757202},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.828000009059906},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.5450000166893005},{"id":"https://openalex.org/keywords/oral-jak-inhibitor","display_name":"oral JAK inhibitor","score":0.5860000252723694}],"concepts":[{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.8198933601379395},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7655715942382812},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7284129858016968},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6277936697006226},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.601861834526062},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.44368916749954224},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3321587145328522}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D002097","descriptor_name":"C-Reactive Protein","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D053613","descriptor_name":"Janus Kinase 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/art.40186","doi":"https://doi.org/10.1002/art.40186","is_oa":true,"landing_page_url":"https://doi.org/10.1002/art.40186","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.40186","source":{"id":"https://openalex.org/S4210186158","display_name":"Arthritis & Rheumatology","issn_l":"2326-5191","issn":["2326-5191","2326-5205"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5656813","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5656813","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis Rheumatol","raw_type":"Text"},{"id":"pmid:28622463","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28622463","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & rheumatology (Hoboken, N.J.)","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:ibn.idsi.md:59026","doi":null,"is_oa":true,"landing_page_url":"https://ibn.idsi.md/vizualizare_articol/59026","pdf_url":null,"source":null,"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Arthritis and Rheumatology 69 (10) 1949-1959","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1002/art.40186","doi":"https://doi.org/10.1002/art.40186","is_oa":true,"landing_page_url":"https://doi.org/10.1002/art.40186","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/art.40186","source":{"id":"https://openalex.org/S4210186158","display_name":"Arthritis & Rheumatology","issn_l":"2326-5191","issn":["2326-5191","2326-5205"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Arthritis & Rheumatology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320319293","display_name":"Gal\u00e1pagos","ror":"https://ror.org/04e4j5d46"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2625769798.pdf","grobid_xml":"https://content.openalex.org/works/W2625769798.grobid-xml"},"referenced_works_count":37,"referenced_works":["https://openalex.org/W149177015","https://openalex.org/W1980230927","https://openalex.org/W1982161030","https://openalex.org/W1985004174","https://openalex.org/W2009870147","https://openalex.org/W2018320089","https://openalex.org/W2019931350","https://openalex.org/W2022819740","https://openalex.org/W2033299724","https://openalex.org/W2038992287","https://openalex.org/W2047345981","https://openalex.org/W2065419533","https://openalex.org/W2072026013","https://openalex.org/W2074438676","https://openalex.org/W2076649595","https://openalex.org/W2079170183","https://openalex.org/W2080708975","https://openalex.org/W2095843897","https://openalex.org/W2096906176","https://openalex.org/W2101217991","https://openalex.org/W2106938542","https://openalex.org/W2110177517","https://openalex.org/W2110523622","https://openalex.org/W2115144341","https://openalex.org/W2126087693","https://openalex.org/W2130002823","https://openalex.org/W2132173287","https://openalex.org/W2149026148","https://openalex.org/W2152348310","https://openalex.org/W2153637692","https://openalex.org/W2156166356","https://openalex.org/W2157198188","https://openalex.org/W2159106700","https://openalex.org/W2170075029","https://openalex.org/W2330734629","https://openalex.org/W2559743688","https://openalex.org/W4230966906"],"related_works":["https://openalex.org/W2555694062","https://openalex.org/W2566103724","https://openalex.org/W2551210591","https://openalex.org/W2562753811","https://openalex.org/W2751345233","https://openalex.org/W2950426289","https://openalex.org/W3019845218","https://openalex.org/W4387404220","https://openalex.org/W2947819355","https://openalex.org/W2554913646"],"abstract_inverted_index":{"OBJECTIVE:":[0],"JAK":[1,36,209],"inhibitors":[2,210],"have":[3],"shown":[4],"efficacy":[5,26,100,292],"in":[6,110,161,177,232,241,293,300],"rheumatoid":[7],"arthritis":[8],"(RA).":[9],"We":[10],"undertook":[11],"this":[12],"study":[13,265],"to":[14,55,87,153,264],"test":[15],"our":[16],"hypothesis":[17],"that":[18],"selective":[19,35,208],"inhibition":[20,222,285],"of":[21,85,96,108,118,146,187,219,286],"JAK-1":[22,251,287],"would":[23],"combine":[24],"good":[25],"with":[27,33,51,132,205,247,288,295],"a":[28,82],"better":[29],"safety":[30,298],"profile":[31,299],"compared":[32],"less":[34,207],"inhibitors.":[37],"METHODS:":[38],"In":[39],"two":[40],"4-week":[41],"exploratory,":[42],"double-blind,":[43],"placebo-controlled":[44],"phase":[45],"IIa":[46],"trials,":[47],"127":[48],"RA":[49,294],"patients":[50,109],"an":[52,124,296],"insufficient":[53],"response":[54,149],"methotrexate":[56],"(MTX)":[57],"received":[58],"filgotinib":[59,133,188,258,289],"(GLPG0634,":[60],"GS-6034)":[61],"oral":[62],"capsules":[63],"(100":[64],"mg":[65,75,136,199],"twice":[66],"daily":[67],"or":[68,73,78,235,269],"30,":[69],"75,":[70],"150,":[71],"200,":[72],"300":[74],"once":[76],"daily)":[77],"placebo,":[79],"added":[80],"onto":[81],"stable":[83],"regimen":[84],"MTX,":[86],"evaluate":[88],"safety,":[89],"efficacy,":[90],"pharmacokinetics":[91],"(PK),":[92],"and":[93,106,142,156,172,181,189,229,271,275],"pharmacodynamics":[94],"(PD)":[95],"filgotinib.":[97],"The":[98,185],"primary":[99,139],"end":[101,140],"point":[102,141],"was":[103,193,216,245,259,281],"the":[104,115,138,157,165,197,276],"number":[105],"percentage":[107],"each":[111],"treatment":[112],"group":[113],"meeting":[114],"American":[116],"College":[117],"Rheumatology":[119],"20%":[120],"improvement":[121],"criteria":[122],"(achieving":[123],"ACR20":[125,148],"response)":[126],"at":[127,134],"week":[128,154],"4.":[129],"RESULTS:":[130],"Treatment":[131],"75-300":[135],"met":[137],"showed":[143],"early":[144],"onset":[145],"efficacy.":[147],"rates":[150],"progressively":[151],"increased":[152],"4,":[155],"Disease":[158],"Activity":[159],"Score":[160],"28":[162],"joints":[163],"using":[164],"C-reactive":[166],"protein":[167],"(CRP)":[168],"level":[169,180],"decreased.":[170],"Marked":[171],"sustained":[173],"improvements":[174],"were":[175,211,254,267],"observed":[176,213],"serum":[178],"CRP":[179],"other":[182,206],"PD":[183],"markers.":[184],"PK":[186],"its":[190],"major":[191],"metabolite":[192],"dose":[194],"proportional":[195],"over":[196],"30-300":[198],"range.":[200],"Early":[201],"side":[202],"effects":[203,225,249],"seen":[204],"not":[212],"(e.g.,":[214],"there":[215],"no":[217,224,230,255],"worsening":[218],"anemia":[220],"[JAK-2":[221],"related],":[223],"on":[226],"liver":[227],"transaminases,":[228],"increase":[231],"low-density":[233],"lipoprotein":[234],"total":[236],"cholesterol).":[237],"A":[238],"limited":[239],"decrease":[240],"neutrophils":[242],"without":[243],"neutropenia":[244],"consistent":[246],"immunomodulatory":[248],"through":[250],"inhibition.":[252],"There":[253],"infections.":[256],"Overall,":[257],"well":[260],"tolerated.":[261],"Events":[262],"related":[263],"drug":[266],"mild":[268],"moderate":[270],"transient":[272],"during":[273],"therapy,":[274],"most":[277],"common":[278],"such":[279],"event":[280],"nausea.":[282],"CONCLUSION:":[283],"Selective":[284],"shows":[290],"initial":[291],"encouraging":[297],"these":[301],"exploratory":[302],"studies.":[303]},"counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":12}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-06-23T00:00:00"}